CPVT: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
mNo edit summary |
||
| Line 3: | Line 3: | ||
''Supervisor: Arthur A.M. Wilde'' | ''Supervisor: Arthur A.M. Wilde'' | ||
'''Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)''' refers to a hereditary disease that is associated with exercise (or adrenergic) induced ventricular arrhythmias and/or cardiac syncope and carries an increased risk of sudden cardiac death. | '''Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)''' refers to a hereditary disease that is associated with exercise (or adrenergic) induced ventricular arrhythmias and/or cardiac syncope and carries an increased risk of sudden cardiac death. | ||
| Line 10: | Line 10: | ||
*The resting ECG is normal and the heart is structurally normal. | *The resting ECG is normal and the heart is structurally normal. | ||
*It is an inheritable cardiac arrhythmia syndrome<cite>arrhythm</cite> with an autosomal dominant (RyR2) or recessive (CASQ2) inheritance. | *It is an inheritable cardiac arrhythmia syndrome<cite>arrhythm</cite> with an autosomal dominant (RyR2) or recessive (CASQ2) inheritance. | ||
*The arrhythmias typically occur in children and adolescents. | *The arrhythmias typically occur in children<cite>tachycardia</cite> and adolescents. | ||
*The mortality rate is approximately 31% by the age of 30 years, if untreated. | *The mortality rate is approximately 31% by the age of 30 years, if untreated. | ||
*The prevalence is estimated to be 1:10.000 in Europe. | *The prevalence is estimated to be 1:10.000 in Europe. | ||
| Line 63: | Line 63: | ||
#Werf pmid=21616285 | #Werf pmid=21616285 | ||
#Wilde pmid=18463378 | #Wilde pmid=18463378 | ||
# | #Werf2 pmid=20851823 | ||
#Priori pmid=12093772 | #Priori pmid=12093772 | ||
#ryanodine pmid=22787013 | #ryanodine pmid=22787013 | ||
</biblio>'' | </biblio>'' | ||